Severe acute respiratory syndrome coronavirus 2 infection, angiotensin-converting enzyme 2 and treatment with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers

Eur J Prev Cardiol. 2022 Jan 11;28(16):e10-e13. doi: 10.1177/2047487320918421.

Authors

Riccardo Sarzani^{1

2}, Federico Giulietti^{1

2}, Chiara Di Pentima^{1

2}, Piero Giordano¹, Francesco Spannella^{1

2}

Affiliations

¹ Internal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS INRCA, Italy.
² Department of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Italy.

No abstract available

MeSH terms

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors*
COVID-19*
Humans
Renin-Angiotensin System

Substances

Angiotensin-Converting Enzyme Inhibitors
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme 2